Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of TAK-771 in Japanese subjects with primary immunodeficiency diseases
jRCT2031210457Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immunoglobulin g + hyaluronidase in Immunogenetic disorder, sponsored by Takeda. Primary endpoint: Serum trough levels of total IgG antibodies after administration of TAK-771 (Epoch 2). Started Jan 2022; status: completed.
02
Drugs
immunoglobulin g + hyaluronidase
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on jRCT2031210457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210457.